Dizal to Showcase New Data on ZEGFROVY® for Lung Cancer Treatment at WCLC 2026

Dizal to Present Innovative Data on ZEGFROVY® at WCLC 2026

Dizal Pharmaceutical, a biopharmaceutical firm focused on producing groundbreaking therapies for cancer and immune system disorders, has declared its intention to reveal the latest clinical research on ZEGFROVY® (sunvozertinib) at the upcoming World Conference on Lung Cancer (WCLC) set to take place from September 12 to 15, 2026, in Seoul, South Korea.

ZEGFROVY® Overview

ZEGFROVY® is an irreversible EGFR (epidermal growth factor receptor) inhibitor aimed at treating patients with non-small cell lung cancer (NSCLC) exhibiting EGFR exon 20 insertion mutations (exon20ins). This treatment option has received approval in both the United States and China for adult patients whose cancers have progressed following platinum-based chemotherapy.

Dizal's efforts to broaden ZEGFROVY®'s therapeutic applications recently included submitting a Supplemental New Drug Application (sNDA) for its use as a first-line therapy based on encouraging results from the multinational Phase 3 WU-KONG28 study, aimed at treatment-naive patients. An exclusive global licensing agreement with AstraZeneca was also announced, signaling the strategic intent to further develop this promising medication.

Upcoming Presentations at WCLC 2026

During the WCLC event, Dizal is slated to present results from several critical studies involving ZEGFROVY®:

Adjuvant Treatment Study: The lead author, Prof. Chang Chen, will share findings from a study examining ZEGFROVY® as an adjuvant treatment for patients with resected stage IB-IIIB NSCLC with EGFR exon20ins. The results highlight promising efficacy, suggesting potential as an earlier intervention for the disease. No new safety concerns have surfaced during the study.

Combination Therapy Study: Prof. Yongchang Zhang will present updated data from a Phase 2 study assessing the combination of ZEGFROVY® with Anlotinib as a first-line treatment for NSCLC with EGFR sensitizing mutations and ongoing co-mutations. This chemotherapy-free regimen continues to demonstrate significant anti-tumor activity alongside a well-managed safety profile, emphasizing its clinical utility.

Conclusion

Dizal’s presentations at WCLC 2026 promise to shed light on the transformative potential of ZEGFROVY® in treating advanced stages of lung cancer. With ongoing studies and the supportive results shown in previous trials, ZEGFROVY® is well-positioned to become a crucial player in the evolving landscape of lung cancer therapeutics.

To learn more about Dizal and its innovative programs, visit Dizal Pharma.